store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
D609 (Tricyclodecan-9-yl-Xanthogenate) 具有广泛的生物活性,包括抗氧化、抗凋亡、抗胆碱能、抗肿瘤、抗炎、抗病毒、抗增殖和神经保护活性。D609 通过引起磷脂酰胆碱 (PC) 特异性磷脂酶 C (PC-PLC) 和鞘磷脂合酶 (SMS) 的竞争性抑制来发挥作用。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 198 | 现货 | ||
5 mg | ¥ 412 | 现货 | ||
10 mg | ¥ 593 | 现货 | ||
25 mg | ¥ 978 | 现货 | ||
50 mg | ¥ 1,430 | 现货 | ||
100 mg | ¥ 2,130 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 449 | 现货 |
产品描述 | D609 (Tricyclodecan-9-yl-Xanthogenate) has a wide range of biological activities including antioxidant, antiapoptotic, anticholinergic, antitumor, anti-inflammatory, antiviral, antiproliferative, and neuroprotective activities.D609 acts by inducing competitive inhibition of PC-specific phospholipase C (PC-PLC) and sphingomyelin synthase (SMS). D609 acts by causing competitive inhibition of PC-specific phospholipase C (PC-PLC) and sphingomyelin synthase (SMS). |
靶点活性 | PC-PLC:6.4 μM (Ki) |
体外活性 | D609 (100 μM; 2 hours) significantly inhibits the proliferation of various cell lines[2].At concentrations of 50, 100, and 200 μM (2 hours), D609 activates caspase-3 at 200 μM, while at 50 and 100 μM, no detectable cleavage is observed[2].D609 (100 μM; 2 hours) markedly inhibits BrdU incorporation in BV-2 microglial cells, leading to G1 phase cell accumulation and a decrease in the number of cells in the S phase[2].D609 (100 μM; 2 hours, followed by 2 or 22 hours of cultivation without D609) increases ceramide levels, upregulates p21 expression, and results in decreased phosphorylation of Rb[4]. |
体内活性 | D609 (2.5 and 10 mg/kg/day; intraperitoneal injection; continuous for 6 weeks) inhibits the progression of pre-existing atherosclerotic lesions in apoE-/- mice and transforms the lesion composition into a more stable phenotype[3].Pre-treatment with D609 (50 mg/kg; intraperitoneal injection; single dose) 30 minutes before intratracheal administration of LPS (3 mg/kg) prevents lipopolysaccharide-induced pulmonary arterial hypertension in adult male Wistar rats[2]. |
分子量 | 266.46 |
分子式 | C11H15KOS2 |
CAS No. | 83373-60-8 |
store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 1 mg/mL (3.75 mM), Sonication is recommended.
DMSO: 80 mg/mL (300.23 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
H2O / DMSO | 1 mM | 3.7529 mL | 18.7645 mL | 37.5291 mL | 93.8227 mL |
DMSO | 5 mM | 0.7506 mL | 3.7529 mL | 7.5058 mL | 18.7645 mL |
10 mM | 0.3753 mL | 1.8765 mL | 3.7529 mL | 9.3823 mL | |
20 mM | 0.1876 mL | 0.9382 mL | 1.8765 mL | 4.6911 mL | |
50 mM | 0.0751 mL | 0.3753 mL | 0.7506 mL | 1.8765 mL | |
100 mM | 0.0375 mL | 0.1876 mL | 0.3753 mL | 0.9382 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
D609 83373-60-8 Apoptosis oxidation-reduction Antioxidant D 609 D-609 Inhibitor inhibitor inhibit